CTLA4 and non-small cell lung carcinoma: Hypofractionated and stereotactic radiotherapy regimens have been tested with durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor) in NSCLC (Pakkala et al., 2020; Twyman-Saint Victor et al., 2015; Zhang et al., 2022), and in combination with nivolumab and ipilimumab in Merkel cell carcinoma (Kim et al., 2022).